295 related articles for article (PubMed ID: 17122430)
1. Cost-effectiveness of intravenous thrombolysis with alteplase within a 3-hour window after acute ischemic stroke.
Ehlers L; Andersen G; Clausen LB; Bech M; Kjølby M
Stroke; 2007 Jan; 38(1):85-9. PubMed ID: 17122430
[TBL] [Abstract][Full Text] [Related]
2. National use of thrombolysis with alteplase for acute ischaemic stroke via telemedicine in Denmark: a model of budgetary impact and cost effectiveness.
Ehlers L; Müskens WM; Jensen LG; Kjølby M; Andersen G
CNS Drugs; 2008; 22(1):73-81. PubMed ID: 18072816
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke: experience from Australian stroke center.
Tan Tanny SP; Busija L; Liew D; Teo S; Davis SM; Yan B
Stroke; 2013 Aug; 44(8):2269-74. PubMed ID: 23780955
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs.
Sandercock P; Berge E; Dennis M; Forbes J; Hand P; Kwan J; Lewis S; Lindley R; Neilson A; Wardlaw J
Stroke; 2004 Jun; 35(6):1490-7. PubMed ID: 15105519
[TBL] [Abstract][Full Text] [Related]
5. A pharmacoeconomic assessment of recombinant tissue plasminogen activator therapy for acute ischemic stroke in a tertiary hospital in China.
Yan X; Hu HT; Liu S; Sun YH; Gao X
Neurol Res; 2015 Apr; 37(4):352-8. PubMed ID: 25297471
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of tissue-type plasminogen activator in the 3- to 4.5-hour time window for acute ischemic stroke.
Tung CE; Win SS; Lansberg MG
Stroke; 2011 Aug; 42(8):2257-62. PubMed ID: 21719767
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of thrombolytic treatment for stroke.
Mar J; Begiristain JM; Arrazola A
Cerebrovasc Dis; 2005; 20(3):193-200. PubMed ID: 16088115
[TBL] [Abstract][Full Text] [Related]
8. Alteplase for the treatment of acute ischaemic stroke: a single technology appraisal.
Jones ML; Holmes M
Health Technol Assess; 2009 Sep; 13 Suppl 2():15-21. PubMed ID: 19804685
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of patient selection using penumbral-based MRI for intravenous thrombolysis.
Earnshaw SR; Jackson D; Farkouh R; Schwamm L
Stroke; 2009 May; 40(5):1710-20. PubMed ID: 19286581
[TBL] [Abstract][Full Text] [Related]
10. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke.
Higashida RT; Furlan AJ; Roberts H; Tomsick T; Connors B; Barr J; Dillon W; Warach S; Broderick J; Tilley B; Sacks D; ;
Stroke; 2003 Aug; 34(8):e109-37. PubMed ID: 12869717
[TBL] [Abstract][Full Text] [Related]
11. Observed Cost and Variations in Short Term Cost-Effectiveness of Therapy for Ischemic Stroke in Interventional Management of Stroke (IMS) III.
Simpson KN; Simpson AN; Mauldin PD; Palesch YY; Yeatts SD; Kleindorfer D; Tomsick TA; Foster LD; Demchuk AM; Khatri P; Hill MD; Jauch EC; Jovin TG; Yan B; von Kummer R; Molina CA; Goyal M; Schonewille WJ; Mazighi M; Engelter ST; Anderson C; Spilker J; Carrozzella J; Ryckborst KJ; Janis LS; Broderick JP;
J Am Heart Assoc; 2017 May; 6(5):. PubMed ID: 28483774
[TBL] [Abstract][Full Text] [Related]
12. Acute 'strokenomics': efficacy and economic analyses of alteplase for acute ischemic stroke.
Quinn TJ; Dawson J
Expert Rev Pharmacoecon Outcomes Res; 2009 Dec; 9(6):513-22. PubMed ID: 19941428
[TBL] [Abstract][Full Text] [Related]
13. Economic impact of using additional diagnostic tests to better select patients with stroke for intravenous thrombolysis in the United Kingdom.
Earnshaw SR; McDade C; Chapman AM; Jackson D; Schwamm L
Clin Ther; 2012 Jul; 34(7):1544-58. PubMed ID: 22695225
[TBL] [Abstract][Full Text] [Related]
14. Would a Large tPA Trial for Those 4.5 to 6.0 Hours from Stroke Onset Be Good Value for Information?
Soeteman DI; Menzies NA; Pandya A
Value Health; 2017; 20(7):894-901. PubMed ID: 28712618
[TBL] [Abstract][Full Text] [Related]
15. Is hospitalization after TIA cost-effective on the basis of treatment with tPA?
Nguyen-Huynh MN; Johnston SC
Neurology; 2005 Dec; 65(11):1799-801. PubMed ID: 16344525
[TBL] [Abstract][Full Text] [Related]
16. Remote ischemic perconditioning in thrombolysed stroke patients: randomized study of activating endogenous neuroprotection - design and MRI measurements.
Hougaard KD; Hjort N; Zeidler D; Sørensen L; Nørgaard A; Thomsen RB; Jonsdottir K; Mouridsen K; Hansen TM; Cho TH; Nielsen TT; Bøtker HE; Østergaard L; Andersen G
Int J Stroke; 2013 Feb; 8(2):141-6. PubMed ID: 22463392
[TBL] [Abstract][Full Text] [Related]
17. A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke.
Boudreau DM; Guzauskas G; Villa KF; Fagan SC; Veenstra DL
Ann Emerg Med; 2013 Jan; 61(1):46-55. PubMed ID: 22633340
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism.
Perlroth DJ; Sanders GD; Gould MK
Arch Intern Med; 2007 Jan; 167(1):74-80. PubMed ID: 17210881
[TBL] [Abstract][Full Text] [Related]
19. A literature review of cost-effectiveness of intravenous recombinant tissue plasminogen activator for treating acute ischemic stroke.
Joo H; Wang G; George MG
Stroke Vasc Neurol; 2017; 2(2):73-83. PubMed ID: 28736623
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of recombinant tissue-type plasminogen activator within 3 hours of acute ischemic stroke: current evidence.
Boudreau DM; Guzauskas GF; Chen E; Lalla D; Tayama D; Fagan SC; Veenstra DL
Stroke; 2014 Oct; 45(10):3032-9. PubMed ID: 25190439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
